Eli Lilly, Mastercard, and AMD Navigate Mixed Performance

Lilly rides strong GLP-1 demand, while Mastercard and AMD face competition pressures

Apr. 17, 2026 at 9:38pm

Got story updates? Submit your updates here. ›

An extreme close-up of the intricate machinery and mechanisms that power the banking industry, conveying a sense of the hidden complexity and scale of modern finance.As major financial institutions navigate rising competition and economic uncertainty, the inner workings of the banking system remain a powerful, if unseen, force.Chicago Today

Eli Lilly's popular GLP-1 drugs like Mounjaro and Zepbound are driving strong sales growth, but the company also faces headwinds like declining Trulicity sales and pricing pressure. Mastercard's revenues rose 16% in 2025, but expenses are also increasing due to investments. AMD is benefiting from strong demand for EPYC processors and Instinct accelerators, but faces stiff competition from Nvidia and Intel.

Why it matters

These three major companies represent key trends in the pharmaceutical, financial services, and semiconductor industries. Lilly's success with GLP-1 drugs highlights the growing importance of diabetes and obesity treatments, while Mastercard and AMD's challenges illustrate the competitive pressures facing established players in their respective markets.

The details

Eli Lilly has seen its shares outperform the industry, driven by robust demand for its GLP-1 drugs. However, the company also faces headwinds like declining sales of Trulicity and pricing pressure on some products. Mastercard's revenues rose 16% in 2025, but expenses are also increasing due to investments in growth initiatives. AMD is benefiting from strong demand for its EPYC processors and Instinct accelerators, but faces stiff competition from Nvidia and Intel.

  • Lilly launched its oral GLP-1 obesity pill, Foundayo, in April 2026.
  • Mastercard paid dividends of $2.8 billion in 2025.

The players

Eli Lilly and Co.

An American pharmaceutical company that develops and markets drugs, including popular GLP-1 medications like Mounjaro and Zepbound.

Mastercard Inc.

A global payments and technology company that provides credit, debit, and prepaid card services.

Advanced Micro Devices, Inc.

An American semiconductor company that designs and produces microprocessors, motherboard chipsets, and other related technology.

Got photos? Submit your photos here. ›

The takeaway

These three companies are navigating a mix of opportunities and challenges in their respective industries. Lilly's success with GLP-1 drugs highlights the growing importance of diabetes and obesity treatments, while Mastercard and AMD's challenges illustrate the competitive pressures facing established players in their markets.